

Info Sheet for Technical description

No. 0018

Organization

* Mandatory fields

Name of Organization*	Myoridge Co. Ltd.		
Address, City, States, Zip, Country*	14 Yoshidakawara-cho, Sakyo-ku, Kyoto, 606-8305, Japan		
URL	https://myoridge.co.jp/en/		
Brief Descriptions of Organization* (Approx. 100 words)	Myoridge is a commercial stage startup that spun out of Kyoto university in Japan. We mainly offer culture media optimization for cell therapy products. Our core competency is creating optimized culture media according to customer needs leveraging our deep scientific expertise and proprietary platform. For example, we have experiences to develop custom-made media for MSC, fibroblast, T cell, DC and NK cell.		
Contact address	Name*	Takeo Suzuki	
	Department* / Position	CEO	
	E-mail* / TEL	suzuki@myoridge.co.jp/070-1465-7892	

What kind of technology do you want to offer? *

- ☐ **A.** Clinical Development Pipelines
- ☒ **B.** Regenerative Medicine-related Consumables / Instruments / Materials / CDMO Services etc.
- ☒ **C.** Platform Technologies(*) that are not included in the above (Group B)

→ Please see **Sheet [A]**→ Please see **Sheet [B]**→ Please see **Sheet [C]**

* Peripheral technologies that contribute to a significant improvement in productivity throughout the value chain of pharmaceuticals, from research and development to manufacturing and ultimately market launch.

If you agree to the following, please check "Yes" below. *

The technologies introduced in this 'Info Sheet' are in the public domain, as they have been published in research papers or have related patent applications.

- ☒ Yes

Do you have any collaborations/partnerships with pharmaceutical companies?

- ☒ Yes
- ☐ No

If you have already received funding from VCs or other sources, up to which stage has the investment round progressed?

- ☐ Angel / Seed (including AMED/JST grants)
- ☐ Series A
- ☐ Series B
- ☒ Series C
- ☐ Series D or further advanced stages

Do you agree to leave your presentation materials at FIRM hands and entrust us to make use of them for the purpose of promoting your partnering opportunities? *

Options*	Comments
☒ Yes	
☐ No	

Filled in by*

Date*

Takeo Suzuki
28-Jul-25

Sheet [C] Platform Technologies *that are not included in Group B***Info Sheet for Technical overview**

No.C-0018

* Mandatoty fields

Title***T cell culture method regulating CD4+ and CD8+ cells ratio, maintaining immature T cells, and increasing proliferation rate of T cells****Description***

We are looking for licensing opportunities of out-licensing of our T cell culture method regulating CD4+ and CD8+ cells ratio, maintaining immature T cells, and increasing proliferation rate of T cells.

Summary of Myoridge's T cell culture methods

-Regulating CD4+ and CD8+ cells ratio changing concentration of specific culture medium components. Compared to the case where CD4 and CD8 CARs are cultured separately at the time of CAR-T induction, the work process can be significantly reduced.

-Higher survival rate and CCR7 expression.

Filled in by*

Takeo Suzuki

Date*

28-Jul-25